Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo comparator, Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: GW685698X Aqueous Nasal Spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Woodstock, Georgia

Conditions: Rhinitis, Seasonal, Allergic
Interventions: PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more

Conditions: Perennial Allergic Rhinitis With Seasonal Variation
Interventions: allergen immunotherapy; Other
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCL Nasal Spray, 0.6%, Fluticasone Propionate Nasal Spray, 50 mcg; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Allergic Conjunctivitis
Interventions: REGN5713, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Seasonal Allergic Rhinitis
Interventions: Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: fluticasone furoate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Orotic acid and Glutathione-(Nutritional Supplements); Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Vitamin D3, Placebo, Fluticasone Propionate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergy Pollen
Interventions: Spiriplex Allergenex Microassay; Diagnostic Test
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more

Conditions: Rhinitis, Allergic, Perennial, Hay Fever
Interventions: Ciclesonide nasal, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hay Fever
Interventions: topical nasal rEV131; Drug
Lead sponsor: Evolutec Group; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: substance P, substance P injections; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Conjunctivitis
Interventions: REGN5713, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Andover, Massachusetts • Lincoln, Nebraska

Conditions: Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions: omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 3
States / cities: Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin

Conditions: Seasonal Allergic Rhinitis
Interventions: 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 29
States / cities: Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more

Conditions: Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions: Not listed
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 6 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Allergy
Interventions: ALK Ragweed Tablet; Biological
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Nasal Congestion
Interventions: Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more

Conditions: Allergy
Interventions: Standardized Allergenic Extract, Cat Hair, Placebo; Biological
Lead sponsor: Antigen Laboratories, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: San Diego, California • Marietta, Georgia • St Louis, Missouri

Conditions: Allergy
Interventions: Grazax; Drug
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

The Efficacy & Safety of the UAS Immunotherapy Protocol

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

Intranasal Steroids and the Nasal Ocular Response

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

Vitamin D Plus Fluticasone Propionate

Microassay and Allergy Skin Prick Test Correlation Study

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

Reduction of IgE Antibody in Human Allergic Subjects

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

Safety of ALK Ragweed Tablet

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

Phase 2 Study in Adults Sensitized to Cat

A Trial of Grazax in Subjects With Hayfever